Should I Buy EUDA? EUDA 2026 Analysis

Should You Buy EUDA Health Holdings Ltd (EUDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.310

1 Day change

0.77%

52 Week Range

4.500

Analysis Updated At

2026/01/28

EUDA is not a good buy right now for a Beginner, long-term investor with $50k–$100k who is impatient and doesn’t want to wait for a cleaner setup. The stock is in a clear bearish trend (price below short/medium/long moving averages) and there are no supportive catalysts (no recent news, no visible institutional/insider accumulation, no analyst support, and no usable financial snapshot). Despite being extremely oversold, that alone is not enough to justify a long-term entry here.

Technical Analysis

Trend/structure: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), which signals a sustained downtrend. Momentum: MACD histogram is negative (-0.0636) and still below zero (bearish), though it is “negatively contracting,” meaning downside momentum may be slowing rather than reversing. Overbought/oversold: RSI(6) at ~13.28 is deeply oversold—this can produce short bounces, but it is not a reliable long-term entry signal by itself when the trend remains bearish. Key levels: The stock closed at 1.32, essentially at S1 (1.33). If it fails to reclaim 1.33–1.71 (Pivot 1.712), the next notable downside level is S2 at 1.094. Upside resistance sits around Pivot 1.712, then R1 2.094. Near-term pattern stats provided: similar-pattern probabilities show slightly negative drift over 1-week (-0.16%) and 1-month (-0.46%), which aligns with the bearish trend. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Technically oversold (RSI ~13) could trigger a short-term relief bounce; MACD downside momentum is contracting (selling pressure may be easing).

Neutral/Negative Catalysts

Primary trend is bearish (SMA_200 > SMA_20 > SMA_5) with price sitting at/just below near-term support (S1 ~1.33). No recent news catalysts in the last week. Hedge funds and insiders show neutral activity (no supportive accumulation trend). No options sentiment available to confirm a bullish turn. No analyst rating/price target trend provided. No congress trading activity to validate interest from influential buyers.

Financial Performance

Financial snapshot unavailable due to data error ("list index out of range"), so latest quarter/season growth trends cannot be assessed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so Wall Street pro/con consensus cannot be validated here. Practically, that means there is no visible analyst-driven support in the dataset to offset the clearly bearish technical picture.

Analyst Rating

Wall Street analysts forecast EUDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EUDA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold